Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 31182382.
- Also identified by DOI 10.1016/j.jaad.2019.03.055.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rosacea is a chronic disease that is characterized by facial skin inflammation and vascular abnormality. Vascular endothelial growth factor (VEGF) is a potent mediator of vascular permeability and inflammation that might play a role in the pathogenesis of rosacea. This study aimed to determine the association between VEGF gene polymorphisms and rosacea. A case-control study design was used to compare 100 patients with rosacea and 100 age- and gender-matched control subjects in terms of VEGF polymorphisms based on polymerase chain reaction and the serum level of VEGF and VEGF receptors based on enzyme-linked immunosorbent assay. Heterozygous and homozygous +405C/G polymorphism of the VEGF gene was observed to increase the risk of rosacea 1.7-fold (95% confidence interval 1.2-4.2) and 2.3-fold (95% confidence interval 1.2-4.2), respectively. There was a significant positive correlation between the severity of rosacea and +405C/G polymorphism of the VEGF gene in patients with erythematotelangiectatic rosacea. Serum VEGF and VEGF receptor levels were measured in the limited number of patients. The present findings indicate that +405C/G polymorphism of the VEGF gene increases the risk of rosacea.
Medical subject headings
- Rosacea
- Vascular Endothelial Growth Factor A